A Novel Treatment Approach: Allergies and Immune Dysregulation in Chronic Inflammatory Illness
An unfortunate dice roll of genetic susceptibility and environmental exposure, immune dysregulation underlies almost every chronic illness on some level and encompasses a wide range of conditions to varying degrees of severity. From simple inhalant allergies to life-threatening autoimmune diseases, more than a third of the population of America deals with one or more of these issues. Unfortunately, all of these problems are also increasing in prevalence due to a myriad number of potential factors, all of which affect our intestinal microbiome and disrupt other natural immune barriers.
Acting as catalysts, toxic metals, artificial and processed ingredients, herbicides, pesticides, mold toxin, refined sugar, Wi-Fi, 4G and 5G electro-smog and glyphosate are just a few of the many players capable of altering genetic expression and exploiting weaknesses in our unique genetic code. Combined with additional factors, this disruption to normal physiology ultimately creates an immunologic “breaking-point.”
Some of these additional factors include: A lack of natural exposure to various pollens and animal dander during the first 7 years of immune development. Introduction of foreign antigenic material into the body before adaptive immunity develops or thymic maturation can occur. Exposure to a viral, bacterial or protozoal infection that either triggers an autoimmune reaction through molecular mimicry or amplifies immune mediated inflammation due to its persistence in the body. Whatever the cause or trigger, allergy and autoimmunity represent a loss of appropriate immune “tolerance.”
Unbeknownst to many, there is an effective way to address this commonly found issue! Low Dose Allergy (LDA) and Low Dose Immunotherapy (LDI) represent novel ways to induce production of antigen specific T-regulatory or T-suppressor cells in the body as a way of restoring immune tolerance to most environmental allergic triggers as well as the endogenous proteins involved with autoimmunity. Initially coined enzyme-potentiated desensitization, treatment of allergies (LDA) involves administering a combination of a unique enzyme with a food, inhalant or chemical mix every seven to eight weeks.
LDI is a newer therapy that operates on similar principles but needs to be more individualized and is designed to address sources of inflammation stimulated from within the body itself. While some of these antigen mixtures contain known proteins involved in autoimmunity such as myelin, collagen or GAD-65, many others involve the use of certain bacterial, viral or parasitic organisms, often in specific combinations such as a Lyme, UTI or skin flora mixture.
The premise behind this is twofold. On the one hand, chronic inflammation can be due to the body continuing to be hyper-reactive to the presence of a latent or non-infectious organism that cannot be eliminated, such as Borrelia, Strep, Candida, EBV or clostridia.
On the other hand, many autoimmune or immune mediated conditions such as arthritis, fibromyalgia, narcolepsy, unexplained neuropathy, neurodegenerative disorders, PANDAS, psoriasis and inflammatory bowel disease, to name a few, were initially triggered by immunologic (cross)-reactions with specific microorganisms.
Examples of this include: Rheumatoid arthritis triggered by reactions to Proteus or Klebsiella, Hashimoto’s thyroiditis from Yersinia, interstitial cystitis from E. coli, Vitiligo and alopecia from H. pylori, Crohn’s disease and Ulcerative Colitis from Mycobacteria, fibromyalgia due to Candida species and even OCD and anxiety from Streptococcus bacteria.
After determining the appropriate dosage and antigen mix that alleviates symptoms for a full two months (the lifecycle of a T-cell), treatment is then administered every eight weeks like in LDA. After a period of time, the body develops immune “memory” cells and therapy can then be delayed by progressively longer periods of time without seeing a return of symptoms. This is in stark contrast to standard allergy shots which typically need to be continued for a life-time in order to maintain a suppressive effect on the immune system in order to prevent a rapid return of symptoms.
Moreover, unlike traditional allergy shots which have a relatively high frequency of adverse reactions, the lower and more individualized doses used in LDA and LDI have never resulted in a single reported cases of anaphylaxis in the hundreds of thousands of doses administered over the last 55 years.
The goal with LDI and LDA is to reestablish normal immunological balance with environmental allergens, foods, chemicals or possibly germs currently or previously found within your body’s ecosystem and all its trillions of microbes, so that the inflammation will calm down or stop entirely.
In this way, your symptoms can eventually go away, you can eat foods or go wherever you like without getting reactions and any remaining microorganisms directly or indirectly involved in your disease process can continue to exist as unavoidable cohabitants in your body. If you are like most people with these illnesses who have tried numerous other therapies only to find none or minimal benefit, it actually increases the likelihood that LDA/LDI will be effective because your condition is probably immune related at some core level.